Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 1 institution in 1 country.
Liming QinDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0003-4263-301X
Moqin QiuDepartment of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Qiuling LinDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0002-3239-4345
Binbin JiangDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0009-0008-4678-0766
Shicheng ZhanDepartment of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, China.ORCID 0009-0007-2266-3939
Xueyan WeiDepartment of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, China.ORCID 0000-0002-6053-2792
Junjie WeiDepartment of Epidemiology and Health Statistics, School of Public Health, Guangxi Medical University, Nanning, China.ORCID 0009-0007-7196-9002
Yingchun LiuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Qiuping WenDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Peiqin ChenDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0009-0003-4013-8194
Yanji JiangDepartment of Scientific Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0003-1751-9645
Zihan ZhouDepartment of Cancer Prevention and Control, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0003-1444-4713
Xiumei LiangDepartment of Disease Process Management, Guangxi Medical University Cancer Hospital, Nanning, China.
Ji CaoDepartment of Cancer Prevention and Control, Guangxi Medical University Cancer Hospital, Nanning, China.
Yizhen GongDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Yuying WeiDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Xiaoxia WeiDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Hongping YuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0002-6128-0398
Guangxi Medical University · CN
Funding
Guangxi Medical and health appropriate Technology opening and popularization and application project S2021022Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education GKE-KF202102Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education GKE-ZZ202104Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education GKE-ZZ202118Youth Program of Scientific Research Foundation of Guangxi Medical University Cancer Hospital YQJ2022-5
6 · The paper itself
Abstract
backgroundAlthough the Notch pathway plays an important role in formation and progression of hepatocellular carcinoma (HCC), few studies have reported the associations between functional genetic variants and the survival of hepatitis B virus (HBV)-related HCC.
methodsIn the present study, we performed multivariable Cox proportional hazard regression analysis to evaluate associations between 36,101 SNPs in 264 Notch pathway-related genes and overall survival (OS) of 866 patients with HBV-related HCC.
resultsIt was found that three independent SNPs (NEURL1B rs4868192, CNTN1 rs444927 and FCER2 rs1990975) were significantly associated with the HBV-related HCC OS. The number of protective genotypes (NPGs) were significantly associated with better survival in a dose-response manner (p
conclusionsThree potentially functional SNPs of NEURL1B, CNTN1 and FCER2 may serve as potential prognostic biomarkers for HBV-related HCC.
Indexed as
Carcinoma, HepatocellularHepatitis B, ChronicLiver NeoplasmsVirus DiseasesGenetic Predisposition to DiseaseGenotypeHepatitis B virusHumansPolymorphism, Single NucleotideRNA, MessengerSignal TransductionRNA, Messengerhepatitis B virushepatocellular carcinomaNotch signaling pathwaysingle nucleotide polymorphismsurvival
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association between novel genetic variants of Notch signaling pathway genes and survival of hepatitis B virus-related hepatocellular carcinoma. · full record | OpenQuestion